Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. 2013

Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
Division of Infection and Immunity and Centre for Sexual Health and HIV Research, University College London, London NW3 2PF, UK.

Antiviral T cell responses in hepatotropic viral infections such as hepatitis B virus (HBV) are profoundly diminished and prone to apoptotic deletion. In this study, we investigate whether the large population of activated NK cells in the human liver contributes to this process. We show that in vitro removal of NK cells augments circulating CD8(+) T cell responses directed against HBV, but not against well-controlled viruses, in patients with chronic hepatitis B (CHB). We find that NK cells can rapidly eliminate HBV-specific T cells in a contact-dependent manner. CD8(+) T cells in the liver microcirculation are visualized making intimate contact with NK cells, which are the main intrahepatic lymphocytes expressing TNF-related apoptosis-inducing ligand (TRAIL) in CHB. High-level expression of the TRAIL death receptor TRAIL-R2 is found to be a hallmark of T cells exposed to the milieu of the HBV-infected liver in patients with active disease. Up-regulation of TRAIL-R2 renders T cells susceptible to caspase-8-mediated apoptosis, from which they can be partially rescued by blockade of this death receptor pathway. Our findings demonstrate that NK cells can negatively regulate antiviral immunity in chronic HBV infection and illustrate a novel mechanism of T cell tolerance in the human liver.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
November 2019, The Journal of infectious diseases,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
March 2013, Molecular therapy : the journal of the American Society of Gene Therapy,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
April 2014, Nature communications,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
October 1998, Oncogene,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
March 2003, European journal of immunology,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
November 1983, International journal of cancer,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
September 2005, Cellular and molecular biology (Noisy-le-Grand, France),
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
February 2005, Molecular immunology,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
January 2020, Theranostics,
Dimitra Peppa, and Upkar S Gill, and Gary Reynolds, and Nicholas J W Easom, and Laura J Pallett, and Anna Schurich, and Lorenzo Micco, and Gaia Nebbia, and Harsimran D Singh, and David H Adams, and Patrick T F Kennedy, and Mala K Maini
November 2008, Free radical research,
Copied contents to your clipboard!